Analyst consensus rating
Foghorn Therapeutics Analyst Rating: Buy
Direct answer
Foghorn Therapeutics's consensus rating is Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $4.17.
Forecast evidence checked October 17, 2026.
Get free Foghorn Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.85
- Average price target
- $4.17
- High price target
- $5.00
- Low price target
- $2.00
- Low target gap
- +8.1%
- Target upside
- +125.2%
- High target gap
- +170.3%
- Target range width
- 162.2%
- Consensus rating
- Buy
- Analysts
- 6
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Foghorn Therapeutics?
Foghorn Therapeutics has a verified Buy consensus. The same dataset has an average price target of $4.17.
How far are Foghorn Therapeutics's low and high targets from the recorded price?
The low target implies +8.1%, while the high target implies +170.3%.
How many analysts are included in Foghorn Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is Foghorn Therapeutics's target upside or downside calculated?
The average target of $4.17 is divided by the recorded price of $1.85, then one is subtracted to produce +125.2%. This does not guarantee a future return.
When was Foghorn Therapeutics's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.